The analysis indicated that the brain cancer patient with higher ACSL5 expression had poor survival; in contrast, the patient with higher ACSL5 expression had good survival in breast, colorectal, lung and ovarian cancer (Fig 6E–6H and S8 Table). This evidence concerns the gene ACSL5 and ovarian cancer.